Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C46/00—Preparation of quinones
  • C07C46/10—Separation; Purification; Stabilisation; Use of additives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4858—Organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/18—Antioxidants, e.g. antiradicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
  • C07C41/01—Preparation of ethers
  • C07C41/34—Separation; Purification; Stabilisation; Use of additives

Definitions

• One or more embodiments of the present invention relate to a method for preserving reduced coenzyme Q10, a method for inhibiting oxidation of reduced coenzyme Q10, and a composition containing reduced coenzyme Q10.
• Coenzyme Q is an essential component that is widely distributed in living organisms, from bacteria to mammals, and is known as a component of the mitochondrial electron transport system in cells in living organisms.
• coenzyme Q10 which has 10 repeating structures in the side chain of coenzyme Q, is the main component, and about 40 to 90% of the coenzyme exists in vivo as a reduced form.
• Physiological actions of coenzyme Q include activation of energy production by mitochondrial activation, activation of cardiac function, stabilization of cell membranes, and protection of cells by antioxidant action.
• QH reduced coenzyme Q10
• Patent Document 1 A general method for obtaining reduced coenzyme Q10 has already been disclosed (Patent Document 1).
• Patent Document 2 describes that crystal polymorphism is observed in reduced coenzyme Q10.
• QH Form II type crystal or “Form II type crystal”
• Form I type crystal of reduced coenzyme Q10 is a conventional reduced coenzyme Q10 (hereinafter referred to as “Form I type crystal of reduced coenzyme Q10”, “QH Form I type crystal” or “Form I It is reported to be much more stable than "type crystals”) and have excellent other physical properties.
• Patent Document 3 as a method for producing reduced coenzyme Q10, after mixing a coenzyme Q10-cyclodextrin clathrate (CoQ10-CD clathrate) with an antioxidant, the A method for producing a reduced CoQ10-CD clathrate by storing in a 100% atmosphere is described.
• Patent Document 3 when a mixture of CoQ10, which is not a CD clathrate, and an antioxidant is stored at 60° C. and a humidity of 75%, the production ratio of reduced CoQ10 is low, whereas CoQ10-CD clathrate and It is described that when a mixture with an antioxidant was stored under the same conditions, a large amount of reduced CoQ10 was produced.
• Patent Documents 4, 5, and 6 a matrix containing a water-soluble excipient or a water-soluble excipient and water-soluble ascorbic is used as reduced coenzyme Q10 having high oxidation stability and high bioabsorbability.
• water-soluble excipients include gum arabic and gelatin.
• Patent Document 7 as a formulation for protecting reduced coenzyme Q10 from oxidation, a solid composition containing reduced coenzyme Q10 is coated with at least one type of coating selected from an oil-soluble coating medium and a water-soluble coating medium.
• a solid preparation of reduced coenzyme Q10 coated with a medium is described, and a method is described in which the preparation is placed in an environment adjusted to a relative humidity of 75% or less.
• Shellac and zein are exemplified as oil-soluble coating media.
• Gelatine, sugar, gum arabic, pullulan, cellulose derivatives and yeast cell walls are exemplified as aqueous coating media.
• Patent Document 8 a capsule containing reduced coenzyme Q10 is manufactured or obtained, and the environment surrounding the capsule is controlled to a relative humidity of 0% or more and 60% or less.
• the storage method for Q10 is described.
• Gelatin and the like are exemplified as the material of the capsule.
• Non-Patent Document 1 describes that the oxygen permeability of a gelatin film containing no glycerin increases tenfold when the relative humidity increases by 20%.
• Non-Patent Document 2 "Oxygen permeability tends to increase by 10 to 105 times as water activity and relative humidity increase.
• the oxygen permeability of a collagen film is 6 when the water activity is 0. .6 ⁇ 10 ⁇ 19 gm ⁇ 1 s ⁇ 1 Pa ⁇ 1 , but becomes 13.68 ⁇ 10 ⁇ 15 gm ⁇ 1 s ⁇ 1 Pa ⁇ 1 when the water activity is 0.93.”
• Non-Patent Document 3 describes that "in general, when the amount of plasticizer, temperature, and relative humidity increase, the oxygen and water vapor permeability of the protein film increases.”
• Patent Documents 4 to 8 all relate to techniques for improving oxidation stability by coating QH with a coating of gas barrier materials such as gelatin, gum arabic and shellac.
• Patent Documents 4 to 8 describe that QH is stabilized when a QH preparation coated with a gas-barrier film such as gelatin is stored at a relative humidity below a predetermined value.
• a QH preparation coated with a gas-barrier film such as gelatin is stored at a relative humidity below a predetermined value.
• QH formulations coated with gas barrier coatings during storage It can be understood that the oxygen permeability of the gas barrier film is reduced and the oxidation of QH is suppressed by setting the relative humidity of the gas barrier film to a predetermined value or less.
• Patent Document 9 describes that a co-crystal containing reduced coenzyme Q10 and a compound such as 3,4-dihydroxybenzoic acid was found as a further form of reduced coenzyme Q10.
• Patent Document 10 describes that reduced coenzyme Q10 and nicotinamide form a co-crystal. Co-crystallization of reduced coenzyme Q10 and one or more other compounds may improve the oxidation stability of reduced coenzyme Q10. Can not.
• Patent Documents 3 to 8 disclose QH products that can prevent oxidation of reduced coenzyme Q10 (QH) and can be stored stably.
• QH reduced coenzyme Q10
• Patent Documents 3 to 8 the use of QH is limited because it requires formulation such as clathration, coating, granular composition, or encapsulation of QH with a specific component.
• QH is not compounded or formulated with a specific component as in Patent Documents 3 to 8
• one or more embodiments of the present invention provide a method for storing QH, a method for suppressing oxidation of QH, and a composition containing QH, which can suppress oxidation of QH.
• the present inventors have unexpectedly found that QH has high oxidation stability in a composition with a low water activity of 0.45 or less, and have completed the following aspects of the present invention.
• a method for storing reduced coenzyme Q10 comprising: A method comprising storing a composition containing reduced coenzyme Q10 and having a water activity of 0.45 or less at 25°C. (2) the composition is a mixed composition in which the reduced coenzyme Q10 and one or more other components are mixed; (1) The method as described in. (3) The composition is a multiphase composition comprising a first phase containing the reduced coenzyme Q10 and a second phase containing one or more other components, which are placed in contact with each other. , (1) The method as described in.
• a method for suppressing oxidation of reduced coenzyme Q10 comprising: A method comprising storing a composition containing reduced coenzyme Q10 and having a water activity of 0.45 or less at 25°C. (5) the composition is a mixed composition in which the reduced coenzyme Q10 and one or more other components are mixed; The method as described in (4). (6) The composition is a multi-phase composition comprising a first phase containing the reduced coenzyme Q10 and a second phase containing one or more other components, which are placed in contact with each other. , The method as described in (4). (7) A composition comprising reduced coenzyme Q10 and having a water activity of 0.45 or less at 25°C.
• composition according to (7) which is a mixed composition in which the reduced coenzyme Q10 and one or more other components are mixed.
• a multi-phase composition comprising a first phase containing the reduced coenzyme Q10 and a second phase containing one or more other components, which are arranged so as to be in contact with each other.
• the composition according to (7) is a mixed composition in which the reduced coenzyme Q10 and one or more other components are mixed.
• the reduced coenzyme Q10 is a Form I crystal of reduced coenzyme Q10, a Form II crystal of reduced coenzyme Q10, a co-crystal consisting of reduced coenzyme Q10 and one or more other compounds, and a reduction It preferably contains one or more selected from amorphous solids of coenzyme Q10, Form I crystal of reduced coenzyme Q10, co-crystal composed of reduced coenzyme Q10 and one or more other compounds, and reduced coenzyme Q10. It is more preferable to contain one or more selected from Form II type crystals of type coenzyme Q10, (1) The method according to any one of (3).
• the reduced coenzyme Q10 is a Form I crystal of reduced coenzyme Q10, a Form II crystal of reduced coenzyme Q10, a co-crystal consisting of reduced coenzyme Q10 and one or more other compounds, and a reduction It preferably contains one or more selected from amorphous solids of coenzyme Q10, Form I crystal of reduced coenzyme Q10, co-crystal composed of reduced coenzyme Q10 and one or more other compounds, and reduced coenzyme Q10. It is more preferable to contain one or more selected from Form II type crystals of type coenzyme Q10, (4) The method according to any one of (6).
• the reduced coenzyme Q10 is a Form I crystal of reduced coenzyme Q10, a Form II crystal of reduced coenzyme Q10, a co-crystal consisting of reduced coenzyme Q10 and one or more other compounds, and a reduction. It preferably contains one or more selected from amorphous solids of coenzyme Q10, Form I crystal of reduced coenzyme Q10, co-crystal composed of reduced coenzyme Q10 and one or more other compounds, and reduced coenzyme Q10. It is more preferable to contain one or more selected from Form II type crystals of type coenzyme Q10, (7)
• the composition according to any one of (9). This specification includes the disclosure contents of Japanese Patent Application Nos. 2021-210438 and 2022-152257, which are the basis of the priority of the present application.
• QH reduced coenzyme Q10
• QH is clathrated or coated with other ingredients, or oxygen is not blocked by formulation such as encapsulation.
• QH can be stably stored by preventing oxidation.
• the method for suppressing the oxidation of QH disclosed in this specification the oxidation of QH can be effectively prevented.
• the composition containing QH disclosed in the present specification oxidation of the QH can be prevented and the QH can be stably stored.
• Reduced coenzyme Q10 in the method according to one or more embodiments of the present invention may partially contain oxidized coenzyme Q10 as long as it contains reduced coenzyme Q10 as a main component.
• the main component is, for example, 50% by weight or more, usually 60% by weight or more, preferably 70% by weight or more, more preferably 80% by weight or more, still more preferably 90% by weight or more, particularly preferably 95% by weight. Above, it means that the content is more than 98% by weight.
• the ratio is the ratio of reduced coenzyme Q10 to the total amount of coenzyme Q10.
• reduced coenzyme Q10 has two crystal polymorphs, Form I and Form II. Specifically, the melting point is around 48° C., and the diffraction angles (2 ⁇ 0.2°) are 3.1°, 18.7°, 19.0°, and 20° in powder X-ray (Cu—K ⁇ ) diffraction.
• the crystal form of reduced coenzyme Q10 showing characteristic peaks at .2° and 23.0° is Form I type crystal, and has a melting point of around 52°C.
• Reduced coenzyme Q10 showing characteristic peaks at angles (2 ⁇ 0.2°) of 11.5°, 18.2°, 19.3°, 22.3°, 23.0° and 33.3° is a Form II crystal.
• the reduced coenzyme Q10 is selected from QH Form I type crystals, QH Form II type crystals, co-crystals composed of QH and one or more other compounds, and amorphous solids of QH. It is preferable to use QH containing one or more selected from QH Form I crystals, co-crystals composed of QH and one or more other compounds, and QH Form II crystals.
• the one or more other compounds contained in the co-crystal composed of QH and one or more other compounds are not particularly limited as long as they are compounds capable of forming a co-crystal with QH. Examples include benzoic acid and derivatives thereof. organic carboxylic acids, including resorcinol, benzyl alcohol, organic alcohols including phenol and its derivatives, urea, nicotinamide, and the like.
• the other one or more compounds may be one or more, and may be one or two or more, preferably one to three compounds.
• the proportion of QH Form I crystals in QH containing Form I crystals is not particularly limited, but is preferably, for example, 50% by weight or more, usually 60% by weight or more, preferably 70% by weight or more, more preferably 70% by weight or more, with respect to the total amount of QH. 80% by weight or more, more preferably 90% by weight or more, particularly preferably 95% by weight or more, especially 98% by weight or more, most preferably 100% by weight Form I type crystals.
• the QH in a form other than the QH Form I crystal that can be included in the QH containing the Form I crystal is selected from QH Form II crystals, co-crystals composed of QH and one or more other compounds, and amorphous solids of QH. One or more can be exemplified.
• the proportion of QH Form II crystals in QH containing Form II crystals is not particularly limited, it is preferably, for example, 50% by weight or more, usually 60% by weight or more, preferably 70% by weight or more, more preferably 70% by weight or more, with respect to the total amount of QH. 80% by weight or more, more preferably 90% by weight or more, particularly preferably 95% by weight or more, especially 98% by weight or more, most preferably 100% by weight Form II crystals.
• the QH in a form other than the QH Form II crystal that can be included in the QH containing the Form II crystal is selected from QH Form I crystal, a co-crystal consisting of QH and one or more other compounds, and an amorphous solid of QH. One or more can be exemplified.
• the ratio of the co-crystal in the QH containing the co-crystal composed of QH and one or more other compounds is not particularly limited, but is preferably, for example, 50% by weight or more, usually 60% by weight or more, preferably 60% by weight or more, relative to the total amount of QH. 70% by weight or more, more preferably 80% by weight or more, even more preferably 90% by weight or more, particularly preferably 95% by weight or more, particularly preferably 98% by weight or more, most preferably 100% by weight of the co-crystal.
• Examples of QH in a form other than the co-crystal that can be included in the QH including the co-crystal include one or more selected from QH Form I type crystal, QH Form II type crystal, and amorphous solid of QH.
• the QH used in one or more embodiments of the present invention need not be pre-formulated.
• the QH is exclusively from one or more selected from non-preformulated QH, such as QH Form I crystals, QH Form II crystals, and co-crystals consisting of QH and one or more other compounds.
• the QH is a pre-formulated QH (e.g., an inclusion complex of QH with a cyclodextrin, a QH dispersed in a matrix containing a water-soluble excipient in a particulate composition, a coating medium in a solid formulation). not QH coated with (or capsules of QH).
• the water-soluble excipient can be, for example, one or more selected from the group consisting of water-soluble polymers, surfactants, sugars, and yeast cell walls.
• the coating medium can be, for example, an oil-soluble coating medium or a water-soluble coating medium.
• the oil-soluble coating medium can be, for example, sugar esters of higher fatty acids, shellac, cellulose derivatives, fatty acids and their ester derivatives, oils and fats, zein and the like.
• Examples of the water-soluble coating medium include gelatin, sugar, gum arabic, sugar esters of higher fatty acids, tragacanth, pectin, pullulan, alginic acid, dried egg white, milk, curdlan, cellulose derivatives, casein, casein compounds, starch, and yeast. It can be a cell wall or the like.
• the capsule is, for example, QH encapsulated with a soft capsule, hard capsule, microcapsule, or the like.
• Materials for the capsule include, for example, gelatin derived from bovine bone, bovine skin, pig skin, fish skin, etc.; seaweed-derived products such as carrageenan and alginic acid that can be used as food additives; locust bean gum, guar gum, etc. Products derived from plant seeds; production agents containing celluloses; starches such as wheat starch, potato starch, sweet potato starch, corn starch, and dextrin.
• a first embodiment of the present invention comprises: A method for storing QH, comprising: A method comprising storing a composition comprising said QH and having a water activity of 0.45 or less at 25°C.
• the method according to the present embodiment it is possible to suppress oxidation of QH and stably store QH. It is generally believed that compounds with low oxidation stability are more susceptible to oxidation as the humidity decreases, due to the increased proportion of oxygen in the air.
• QH is stabilized in a state contained in a composition having a water activity of 0.45 or less at 25 ° C., which is contrary to the above-mentioned common theory. It is possible to keep QH stable. It is possible. The preparation of said composition is easy to carry out. Therefore, the method according to this embodiment can be a means for stabilizing QH efficiently at low cost.
• QH in the form of QH Form II crystals and co-crystals composed of QH and one or more other compounds have high production costs themselves, so the QH residual rate after storage (see Examples for definition) is 85% or more. are required in order to provide QH of said form at a reasonable price.
• the method according to the present embodiment is preferable because the QH residual rate of QH containing at least one of a Form II crystal and a co-crystal composed of QH and one or more other compounds can be 85% or more.
• QH in the form of QHFormI type crystal can be produced at low cost, but is susceptible to oxidation. of QH at an appropriate price.
• the method according to the present embodiment is preferable because the QH residual rate after storage of QH containing Form I crystals can be 40% or more.
• composition containing QH and having a water activity of 0.45 or less at 25°C in the method according to the present embodiment will be described below.
• the water activity of the composition can be measured by a conventional method.
• the water activity of the composition at 25°C may be 0.45 or less, preferably 0.43 or less, more preferably 0.42 or less, more preferably 0.40 or less, and more preferably 0.38. Below, it is particularly preferably 0.33 or less.
• the composition may contain one or more other ingredients in addition to QH.
• the one or more other ingredients may be ingredients that are used in combination with QH, and include, for example, ingredients that are acceptable as foods, cosmetics, or pharmaceuticals.
• the one or more other components are preferably substances that adsorb water in order to adjust the water activity of the composition to 0.45 or less at 25°C.
• a substance that adsorbs water is a substance that adsorbs water vapor in the gas phase surrounding the composition.
• the substance that adsorbs water has a water activity of 0.45 or less, preferably 0.43 or less, more preferably 0.42 or less, and more preferably 0.40 or less at the temperature of the environment in which the composition is to be stored. , more preferably 0.38 or less, particularly preferably 0.33 or less.
• substances that adsorb water that can be used as the one or more other components include celluloses, starches, sugars, other water-soluble polymer compounds, silicon dioxide, and the like. Celluloses, starches, sugars. and one or more selected from other water-soluble polymer compounds are preferred.
• celluloses examples include crystalline cellulose, cellulose powder, methylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose and salts thereof.
• starches examples include wheat starch, potato starch, sweet potato starch, corn starch, dextrin, hydroxypropyl starch, starch acetate, oxidized starch, starch octenylsuccinate and salts thereof, and partially pregelatinized starch.
• the dextrin is not particularly limited as long as it is a decomposition product of starch, and both low-molecular-weight dextrin and high-molecular-weight dextrin can be suitably used.
• maltodextrin, cyclodextrin, cluster dextrin, etc. can also be suitably used.
• sugars examples include monosaccharides such as glucose, fructose, galactose, arabinose, xylose and mannose; disaccharides such as maltose, sucrose, lactose and trehalose; oligosaccharides such as fructooligosaccharides, soybean oligosaccharides, galactooligosaccharides and xylooligosaccharides; Examples include sugar alcohols such as sorbitol, maltitol, erythritol, lactitol, and xylitol.
• water-soluble polymer compounds include gum arabic, gelatin, agar, tragacanth, pectin, carrageenan, casein, casein compounds, dried egg white, milk, curdlan, alginates, soybean polysaccharides, pullulan, xanthan gum, locust bean gum. etc. can be exemplified.
• the composition is a mixed composition in which QH and one or more other ingredients are mixed.
• the mixed composition as a whole can be a food, cosmetic or pharmaceutical acceptable composition.
• the mixed composition may be a mixed composition in which QH and one or more other components are uniformly mixed, or a mixed composition in which QH and one or more other components are nonuniformly mixed.
• a homogeneously mixed mixed composition refers to a composition comprising QH and one or more other ingredients, wherein the concentration distribution of QH is uniform or substantially uniform throughout the composition.
• a homogeneously mixed composition can be obtained, for example, by thoroughly mixing QH with one or more other ingredients.
• a mixed composition that is mixed inhomogeneously refers to a composition that contains QH and one or more other components and that has a non-uniform concentration distribution of QH.
• a non-uniformly mixed mixed composition can be obtained, for example, by adding QH to one or more other ingredients such as food ingredients.
• the composition is a multi-phase composition comprising a first phase comprising QH and a second phase comprising one or more other ingredients, placed in contact with each other.
• Said multi-phase composition as a whole can be a food, cosmetic or pharmaceutically acceptable composition, and if the first and second phases are separable, at least the first phase comprises food, It can be a cosmetically or pharmaceutically acceptable composition.
• the first phase refers to a phase composed of QH or a homogeneous phase containing QH.
• the second phase refers to a phase that can contact the first phase without being mixed.
• the multiphase composition can be, for example, a laminate of the first phase and the second phase, or a structure in which one of the first phase and the second phase is supported by the other.
• An example of the multiphase composition includes a first phase composed of particles containing QH and a second phase composed of one or more other matrix-like components, and the first phase is supported on the second phase. There are other things.
• Another example of the multi-phase composition includes a first phase containing QH and a second phase containing a substance that adsorbs water, and the first phase and the second phase are arranged to contact each other. What was done is mentioned.
• the content of QH in the composition is not particularly limited.
• the content of QH relative to the total mass of the composition may be, for example, 0.01% by mass or more, preferably 0.1% by mass or more, more preferably 1% by mass or more, for example 99% by mass or less. , preferably 90% by mass or less, more preferably 50% by mass or less.
• the temperature at which the composition is stored in the method according to the present embodiment is, for example, -25°C or higher and 50°C or lower, preferably -20°C or higher, -10°C or higher, 0°C or higher, and 4°C or higher. , 10°C or higher, 15°C or higher, 20°C or higher or 25°C or higher, preferably 45°C or lower or 40°C or lower. Said temperature may in particular be 25°C or 40°C.
• the period for storing the composition in the method according to the present embodiment is not particularly limited as long as it is a period from after manufacture to use of the product, and can be appropriately adjusted according to storage conditions such as temperature, but is preferably 3 days or more, 1 week or more, or 2 weeks or more, for example, 5 years or less, usually 3 years or less, preferably 2 years or less, more preferably 1 year or less, further preferably 6 months or less, further preferably 8 weeks It can be less than, most preferably less than 6 weeks, less than 5 weeks or less than 4 weeks.
• the composition When storing the composition in the method according to the present embodiment, it is preferable to store the composition in a container and store it as a sealed package in order to prevent volatilization of water.
• the package may contain a gas phase within the container, and the gas phase may be air.
• a package containing air as a gas phase can be manufactured at a lower cost than a package containing a gas phase of an inert gas such as nitrogen, which is preferable.
• a second embodiment of the present invention comprises: A method of inhibiting oxidation of QH, comprising: A method comprising storing a composition comprising QH and having a water activity of 0.45 or less at 25°C.
• the oxidation of QH can be efficiently suppressed at low cost.
• the respective features and preferred aspects of the QH, the composition, and the step of preserving the composition are as described for the method according to the first embodiment.
• a third embodiment of the present invention is It relates to a composition comprising QH and having a water activity of 0.45 or less at 25°C.
• Oxidation of QH in the form of a composition according to the present embodiment is effectively suppressed.
• composition according to this embodiment the QH and the characteristics and preferred aspects of each of the compositions are as described for the method according to the first embodiment.
• reduced coenzyme Q10 (trade name: Kaneka QH) manufactured by Kaneka Corporation was used as reduced coenzyme Q10 Form I type crystal (QH Form I type crystal).
• the weight ratio of reduced coenzyme Q10 to total coenzyme Q10 (that is, reduced coenzyme Q10/(oxidized coenzyme Q10+reduced coenzyme Q10)) is defined as the “QH ratio”.
• the QH ratio was obtained by the following HPLC analysis.
• the QH ratio at the end of the evaluation when the QH ratio at the start of the evaluation is 100 is defined as the “QH residual ratio”, and the QH residual ratio obtained from the following formula is the oxidation stability. was used as a measure of
• QH residual rate (%) 100 ⁇ QH ratio at the end of evaluation / QH ratio at the start of evaluation
• Example 5 Preserving reduced coenzyme Q10 in a composition with adjusted water activity
• the QHFormII type crystals and the respective excipients shown in Table 1 were mixed at a weight ratio of 1:1 to obtain a QHFormII type crystal-containing composition.
• 0.2 g of the above composition was placed in each glass bottle (volume 33 ml) and sealed. After storing this package under the conditions of 40° C. and 75% relative humidity for 4 weeks, the QH residual rate was determined.
• the water activity of the composition at 25° C. was measured and shown in Table 1 together with the QH residual ratio.
• Example 2 QHFormII type crystals and gum arabic dried using a vacuum dryer were mixed at a weight ratio of 1:1 to obtain a QHFormII type crystal-containing composition. 0.03 g of the above composition was placed in a glass bottle (volume 10 ml) and sealed. After storing this package under conditions of 40° C. and 75% relative humidity or 25° C. and 60% relative humidity for 4 weeks, the QH residual ratio was determined. In addition, the water activity of the composition at 25° C. was measured and shown in Table 2 together with the QH residual ratio.
• Example 3 QHFormI type crystals and carboxymethyl cellulose were mixed at a weight ratio of 1:1 to obtain a QHFormI type crystal-containing composition.
• 0.2 g of the above composition was placed in a glass bottle (volume 33 ml) and sealed. After storing this package under conditions of 40° C. and relative humidity of 75% for 2 weeks, the QH residual rate was determined.
• the water activity of the composition at 25° C. was measured and shown in Table 4 together with the QH residual ratio.
• Example 4 QHForm I type crystals and gum arabic dried using a vacuum dryer were mixed at a weight ratio of 1:1 to obtain a QH Form I type crystal-containing composition. 0.03 g of the above composition was placed in a glass bottle (volume 10 ml) and sealed. After storing this package under conditions of 25° C. and 60% relative humidity for 4 weeks, the QH residual rate was determined. In addition, the water activity of the composition at 25° C. was measured and shown in Table 5 together with the QH residual ratio.
• Example 5 0.2 g of a co-crystal composed of QH and nicotinamide was packed in an open state in a package whose internal relative humidity was adjusted to 11%. At this time, the water activity of the cocrystal in the package was 0.11. After storing the package at 40° C. for 2 weeks, the QH residual rate was determined.
• Example 10 The results obtained in Example 10 and Comparative Example 3 are summarized and shown in Table 7.
• Table 7 reveals that QH present in co-crystals composed of QH and nicotinamide is also kept stable in compositions with a water activity of 0.45 or less.
• a preferred range can be defined by arbitrarily combining the upper and lower limits of the numerical range
• a preferred range can be defined by arbitrarily combining the upper limits of the numerical range
• the lower limit of the numerical range Any combination of values can be used to define a preferred range.
• a numerical range represented using the symbol "-" includes the numerical values described before and after the symbol "-" as lower and upper limits, respectively.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Epidemiology (AREA)
• Toxicology (AREA)
• Dermatology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)

Priority Applications (5)

Applications Claiming Priority (4)

Publications (1)

Family

ID=86902592

Family Applications (1)

Country Status (5)

Citations (12)

• 2022
  • 2022-12-21 WO PCT/JP2022/047023 patent/WO2023120558A1/ja not_active Ceased
  • 2022-12-21 EP EP22911260.2A patent/EP4454644A4/en active Pending
  • 2022-12-21 US US18/722,374 patent/US20250059124A1/en active Pending
  • 2022-12-21 AU AU2022420270A patent/AU2022420270B2/en active Active
  • 2022-12-21 JP JP2023569480A patent/JPWO2023120558A1/ja active Pending

Patent Citations (12)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events